Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Can Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?

NCT03878459 is registered in ClinicalTrials.gov with The University of Texas Health Science Center at San Antonio as lead sponsor.

NCT NCT03878459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03878459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Can Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Lead sponsor
The University of Texas Health Science Center at San Antonio
Phase
Phase 4
Overall status
Active, not recruiting
Start date
August 8, 2019
Completion date
December 31, 2027
Enrollment
120 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus